24.47
0.27 (1.12%)
Previous Close | 24.20 |
Open | 23.74 |
Volume | 548,566 |
Avg. Volume (3M) | 634,198 |
Market Cap | 1,153,493,760 |
Price / Earnings (TTM) | 8.87 |
Price / Sales | 1.81 |
Price / Book | 1.62 |
52 Weeks Range | |
Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
Profit Margin | 19.38% |
Operating Margin (TTM) | 21.87% |
Diluted EPS (TTM) | 2.76 |
Quarterly Revenue Growth (YOY) | -0.80% |
Quarterly Earnings Growth (YOY) | -41.40% |
Total Debt/Equity (MRQ) | 86.86% |
Current Ratio (MRQ) | 2.95 |
Operating Cash Flow (TTM) | 193.17 M |
Levered Free Cash Flow (TTM) | -3.71 M |
Return on Assets (TTM) | 7.60% |
Return on Equity (TTM) | 19.90% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
Stock | Amphastar Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 3.5 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 2.75 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Insiders | 23.19% |
% Held by Institutions | 72.88% |
52 Weeks Range | ||
Price Target Range | ||
High | 35.00 (Wells Fargo, 43.03%) | Buy |
Median | 32.00 (30.77%) | |
Low | 30.00 (JP Morgan, 22.60%) | Hold |
Average | 32.33 (32.12%) | |
Total | 1 Buy, 2 Hold | |
Avg. Price @ Call | 25.76 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
JP Morgan | 12 May 2025 | 30.00 (22.60%) | Hold | 24.34 |
Wells Fargo | 08 May 2025 | 35.00 (43.03%) | Buy | 24.65 |
Piper Sandler | 21 Mar 2025 | 32.00 (30.77%) | Hold | 28.29 |
No data within this time range.
Date | Type | Details |
---|---|---|
22 May 2025 | Announcement | Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
09 May 2025 | Announcement | Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference |
07 May 2025 | Announcement | Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 |
30 Apr 2025 | Announcement | Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025 |
03 Apr 2025 | Announcement | Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
28 Mar 2025 | Announcement | International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |